Myelodysplastic syndromes: From pathogenesis and prognosis to treatment

Seminars in Hematology

Volumn 41, Issue 2 SUPPL. 4, 2004, Pages 6-12

  Fenaux, Pierre ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 5 AZA 2' DEOXYCYTIDINE; AMIFOSTINE; ANTHRACYCLINE; ARSENIC TRIOXIDE; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DNA METHYLATION INHIBITOR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TRANSFUSION; CHROMOSOME ABERRATION; CYTOPENIA; DNA HYPERMETHYLATION; DNA METHYLATION; DRUG EFFICACY; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HUMAN; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; LEUKEMIA REMISSION; MOLECULAR BIOLOGY; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 2442584301     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2004.02.002     Document Type: Article

References (39)

1. Heaney ML, Golde DW: Myelodysplasia. N Engl J Med 340: 1649-1660, 1999
2. Cheson BD: The myelodysplastic syndromes. Oncologist 2:28-39, 1997
3. Raza A, Gezer S, Mundle S, et al: Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268-276, 1995
4. Shetty V, Hussaini S, Broady-Robinson L, et al: Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: Apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 96:1388-1392, 2000
5. Lepelley P, Campergue L, Grardel N, et al: Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol 95:368-371, 1996
6. Albitar M, Manshouri T, Shen Y, et al: Myelodysplastic syndrome Is not merely "preleukemia." Blood 100:791-798, 2002
7. Fenaux P: Myelodysplastic syndromes. Hematol Cell Ther 38:363-380, 1996
8. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
9. Baxter EJ, Kulkarni S, Vizmanos JL, et al: Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol 120:251-256, 2003
10. Apperley JF, Gardembas M, Melo JV, et al: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487, 2002
11. Cortes J, Giles F, O'Brien S, et al: Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 97:2760-2766, 2003
12. Sitailo S, Sood R, Barton K, et al: Forced expression of the leukemia-associated gene EVI1 in ES cells: A model for myeloid leukemia with 3q26 rearrangements. Leukemia 13: 1639-1645, 1999
13. Senyuk V, Chakraborty S, Mikhail FM, et al: The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. Oncogene 21:3232-3240, 2002
14. Uchida T, Kinoshita T, Nagai H, et al: Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 90:1403-1409, 1997
15. Quesnel B, Guillerm G, Vereecque R, et al: Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985-2990, 1998
16. Mondrem JJ, Leifer E, Bahceci E, et al: Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137:156-163, 2002
17. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982
18. Germing U, Gattermann N, Strupp C, et al: Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leuk Res 24:983-992, 2000
19. Sierra J, Perez WS, Rozman C, et al: Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100:1997-2004, 2002
20. Deeg HJ, Storer B, Slattery JT, et al: Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201-1207, 2002
21. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348, 1998
22. Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860, 2001
23. List AF, Schiller GJ, Mason J, et al: Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary findings in a phase 2 clinical study. Blood 102:423, 2003 (abstr)
24. Vey N, Dreyfus F, Guerci A, et al: Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary results of a phase 1/2 study. Blood 102:422a-423, 2003 (abstr)
25. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440, 2002
26. List AF, Byrd JC, Fenaux P, et al: Comparative trial of zacitidine versus conventional care in high-risk MDS patients: Methodologic challenges in designing an international survival trial. Blood 102:333b-334, 2003 (abstr)
27. Wijermans P, Lubbert M, Verhoef G, et al: Low-dose 5-aza-2′ -deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962, 2000
28. Wijermans PW, Luebbert M, Verhoef G: Low dose decitabine for elderly high-risk MDS patients: Who will respond? Blood 100:96-97a, 2002 (abstr)
29. Wijermans PW, Luebbert M, Verhoef G: LDH is an important risk factor to predict survival in patients with MDS treated with 5-aza-2′-deoxycytidine (decitabine). Blood 102:424, 2003 (abstr)
30. Kurzrock R, Cortes J, Kantarjian H: Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol 39:20-24, 2002
31. Lancet JE, Gojo I, Gotlib J, et al: Tipifarnib (Zarnestra) in previously untreated poor-risk AML and MDS: Interim results of a phase 2 trial. Blood 102:176, 2003 (abstr)
32. Feldman EJ, Cortes J, Holyoake TL, et al: Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome. Blood 102:421, 2003 (abstr)
33. Raza A, Meyer P, Dutt D, et al: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958-965, 2001
34. Strupp C, Germing U, Aivado M, et al: Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16:1-6, 2002
35. List AF, Kurtin S, Glinsmann-Gibson BJ, et al: Efficacy and safety of cc5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS). Blood 102: 184, 2003 (abstr)
36. Steensma DP, Dispenzieri A, Moore SB, et al: Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 101:2156-2158, 2003
37. Saunthararajah Y, Nakamura R, Nam JM, et al: HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100:1570-1574, 2002
38. Gore SD, Weng LJ, Zhai S, et al: Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 7:2330-2339, 2001
39. Gore SD, Weng LJ, Figg WD, et al: Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 8:963-970, 2002